Charles Schwab
ODT

Charles Schwab’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Charles Schwab’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-19,636
Closed -$27K – 3680
2021
Q4 		$27K Hold
19,636
– – ﹤0.01% 3565
2021
Q3 		$58K Sell
19,636
-60,800
-76% -$202K ﹤0.01% 3436
2021
Q2 		$281K Sell
80,436
-49,618
-38% -$170K ﹤0.01% 3249
2021
Q1 		$445K Buy
130,054
+5,784
+5% +$109K ﹤0.01% 3119
2020
Q4 		$2.39M Buy
124,270
+36,614
+42% +$565K ﹤0.01% 2547
2020
Q3 		$1.18M Buy
87,656
+6,234
+8% +$177K ﹤0.01% 2639
2020
Q2 		$3.45M Buy
81,422
+14,592
+22% +$472K ﹤0.01% 2202
2020
Q1 		$1.85M Sell
66,830
-4,047
-6% -$118K ﹤0.01% 2303
2019
Q4 		$2.3M Buy
70,877
+1,736
+3% +$53.8K ﹤0.01% 2374
2019
Q3 		$1.8M Buy
69,141
+13,936
+25% +$466K ﹤0.01% 2416
2019
Q2 		$2.03M Buy
55,205
+1,150
+2% +$27.6K ﹤0.01% 2367
2019
Q1 		$1.2M Buy
54,055
+5,566
+11% +$97.3K ﹤0.01% 2506
2018
Q4 		$683K Buy
48,489
+2,825
+6% +$44K ﹤0.01% 2657
2018
Q3 		$887K Buy
45,664
+11,527
+34% +$235K ﹤0.01% 2660
2018
Q2 		$754K Buy
34,137
+5,601
+20% +$130K ﹤0.01% 2670
2018
Q1 		$605K Buy
+28,536
New +$673K ﹤0.01% 2683

Other funds holding ODT

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Charles Schwab's ODT Position: Q1 2022 in Review

Charles Schwab sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2022, closing a stake of 19,636 shares — an estimated $27K sold.

Charles Schwab first reported a position in ODT in Q1 2018 and held it in 16 quarters. The position peaked at $3.45M in Q2 2020. 8 funds tracked by Wall St. Rank hold ODT as of Q1 2022.

  • Charles Schwab reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Charles Schwab sold 19,636 Odonate Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $27K.
  • Charles Schwab first reported a position in Odonate Therapeutics, Inc. Common Stock in Q1 2018 and held it in 16 quarters.
  • Charles Schwab's Odonate Therapeutics, Inc. Common Stock position peaked at $3.45M in Q2 2020.
  • 8 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Charles Schwab's 13F filing for Q1 2022, filed 13 May 2022.